Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart

Journal of Diabetes

Volumn 7, Issue 2, 2015, Pages 270-278

  Tamborlane, William V ^a   Renard, Eric ^f   Wadwa, R Paul ^b   Blevins, Thomas ^c   Jacober, Scott J ^d   Liu, Rong ^d   D'Souza, Deborah N ^e   Rees, Tina M ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Texas Diabetes and Endocrinology   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e SYNEOS HEALTH   (United States)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Insulin aspart; Insulin infusion; Insulin lispro; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN LISPRO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION SET CLOGGING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; TREATMENT DURATION; ANALYSIS; CHINA; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FOLLOW UP; POSTPRANDIAL STATE; PROGNOSIS; RISK FACTOR;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CHINA; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN INFUSION SYSTEMS; INSULIN LISPRO; MALE; POSTPRANDIAL PERIOD; PROGNOSIS; RISK FACTORS;

EID: 84924033819     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12162     Document Type: Article

References (9)

1. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994; 43: 396-402.
2. Zinman B, Tildesley H, Chiasson TJ, Tsue E, Strack T. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes. 1997; 46: 440-443.
3. American Diabetes Association. Living with Diabetes: Insulin Pumps. American Diabetes Association, 2013. Available from: http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/insulin-pumps.html (accessed 9 May 2014).
4. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM. Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008; 31: 210-215.
5. Bode B, Weinstein R, Bell D etal. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: A randomized study in type 1 diabetes. Diabetes Care. 2002; 25: 439-444.
6. Swan KL, Dziura JD, Steil GM etal. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009; 32: 240-244.
7. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008; 31: 1473-1478.
8. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics. 1965; 21: 467-480.
9. Guidance for Industry. Diabetes Mellitus: Developing drugs and therapeutic biologics for treatment and prevention. 2008; 1-30. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf (accessed 17 May 2013).